Joshua Schafer
Director/Board Member bei PHARNEXT SCA
Vermögen: 20 993 $ am 31.03.2024
Profil
Joshua Schafer is currently a Director at Pharnext SA, a Director at Shuttle Pharmaceuticals, Inc., a Director at Acer Therapeutics, Inc., an Independent Director at Shuttle Pharmaceuticals Holdings, Inc., an Advisor at DRI Capital, Inc., and the Chief Commercial Officer at Zevra Therapeutics, Inc. He previously worked as the General Manager-Autoimmune & Rare Disease at Mallinckrodt Pharmaceuticals Ltd.
and as the Head-Oncology Franchise at Astellas Pharma, Inc. Mr. Schafer completed his undergraduate degree at the University of Notre Dame and holds an MBA from Northwestern University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ZEVRA THERAPEUTICS, INC.
0,01% | 22.03.2024 | 3 500 ( 0,01% ) | 20 300 $ | 31.03.2024 |
| 21.03.2024 | 1 707 ( 0,01% ) | 693 $ | 31.03.2024 |
Aktive Positionen von Joshua Schafer
| Unternehmen | Position | Beginn |
|---|---|---|
| PHARNEXT SCA | Director/Board Member | 28.12.2022 |
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Director/Board Member | 01.01.2019 |
| ZEVRA THERAPEUTICS, INC. | Corporate Officer/Principal | 09.01.2023 |
| ACER THERAPEUTICS INC. | Director/Board Member | 17.11.2023 |
Mallinckrodt Pharmaceuticals Ltd.
 Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Pharmaceuticals Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The private company is based in Staines Upon Thames, UK and was founded in 2015. | Corporate Officer/Principal | 01.01.2015 |
Shuttle Pharmaceuticals, Inc.
 Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Director/Board Member | - |
DRI Capital, Inc.
 DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Consultant / Advisor | - |
Ehemalige bekannte Positionen von Joshua Schafer
| Unternehmen | Position | Ende |
|---|---|---|
| ASTELLAS PHARMA INC. | Corporate Officer/Principal | - |
Ausbildung von Joshua Schafer
| University of Notre Dame | Undergraduate Degree |
| Northwestern University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| ASTELLAS PHARMA INC. | Health Technology |
| PHARNEXT SCA | Health Technology |
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Finance |
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Health Technology |
Mallinckrodt Pharmaceuticals Ltd.
Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Pharmaceuticals Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The private company is based in Staines Upon Thames, UK and was founded in 2015. | Health Technology |
Acer Therapeutics, Inc.
 Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA. | Health Technology |
